CELLECTIS news, videos and press releases - Page 4
For more news please use our advanced search feature.
CELLECTIS - More news...
CELLECTIS - More news...
- Cellectis Announces Positive Preliminary Clinical Data for UCART22 in ALL and UCART123 in AML
- Cellectis Announces Positive Preliminary Clinical Data for UCART22 in ALL and UCART123 in AML
- Cellectis to Host a Live Webcast and Provide a Company Update on December 13, 2022
- Cellectis Presents Pre-Clinical Data on TALEN®-edited Smart CAR T-cells Overcoming Key Challenges of Targeting Solid Tumors at SITC 2022
- Cellectis Publishes Manuscript in Frontiers Bioengineering and Biotechnology Unveiling Efficient Multitool/Multiplex Gene Engineering combining TALEN® and TALE Base Editors (TALE-BE)
- Monthly information on share capital and company voting rights
- Cellectis Provides Business Update and Reports Financial Results for Third Quarter and First Nine Months 2022
- Cellectis to Showcase Clinical Data from AMELI-01 and Preclinical Data from UCARTCS1 at ASH 2022
- Cellectis to Report Third Quarter 2022 Financial Results
- Cellectis Presents Data on Two TALEN®-based Gene Therapy Preclinical Programs for Patients with Sickle Cell Disease and Mucopolysaccharidosis type I at ESGCT 2022
- Monthly information on share capital and company voting rights
- Cellectis to Present Pre-Clinical Data on TALEN®-edited Smart CAR T-cells Supporting Improved Solid Tumor Targeting at the Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting
- Cellectis Appoints Mark Frattini, M.D., Ph.D. as Chief Medical Officer
- Monthly information on share capital and company voting rights
- Cellectis Announces Participation in Four Upcoming Investor Conferences in September
- Monthly information on share capital and company voting rights
- Cellectis Provides Business Update and Reports Financial Results for Second Quarter 2022
- Cellectis Receives IND clearance for UCART20x22, its First in-house Manufactured Product Candidate for the Treatment of B-cell Malignancies
- Cellectis to Report Second Quarter 2022 Financial Results
- Cellectis Publishes Article in Nature Communications Unveiling Novel Immune-Evasive Universal Allogeneic CAR T-cells with Potential for Improved Persistence
- Cellectis Announces the Appointment of Axel-Sven Malkomes & Dr. Donald A Bergstrom, M.D., Ph.D., to its Board of Directors
- Cellectis S.A. Reports Results from Annual Shareholders’ General Meeting Held on June 28, 2022
- Monthly information on share capital and company voting rights
- Cellectis’ Annual Shareholders’ General Meeting to be Held on June 28, 2022
- Cellectis Presents Research Data on a Novel Immune-Evasive Universal CAR T-cell at ASGCT
- Cellectis Provides Business Update and Reports Financial Results for First Quarter 2022
- Monthly information on share capital and company voting rights
- Cellectis to Report First Quarter 2022 Financial Results
- Calyxt, Inc., Cellectis’ Majority-Owned Subsidiary, Reports Its First Quarter 2022 Financial Results
- Cellectis Publishes Two Articles in Nature Communications Providing Strong Preclinical Validation of UCART123 to Treat AML and BPDCN
